Notice names this product. Fresenius Kabi USA’s Naropin (ropivacaine hydrochloride Injection is named in FDA Class II recall D-0727-2026. Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies. Agency-reported hazard: Presence of Particulate Matter: Hair was found in products Identifying details: Lot #: 6133436, Exp. Date 10/2028. Units affected: 92,600 vials. Status: Ongoing.
This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.
If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.
Presence of Particulate Matter: Hair was found in products
Company / brand: Fresenius Kabi USA
Affected product: Naropin (ropivacaine hydrochloride Injection
Official ID D-0727-2026 · Official record ↗
See all Fresenius Kabi USA recalls →
Found something wrong or missing? Report a data error.
Compiled from connected official public-domain government data. Sources last checked September 7, 2026 at 6:00 AM UTC.